Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520467-40-00

Acronym

MK-3120-003

Enrollment

Registered

2025-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

Brief summary

Number of Participants Who Experience a Dose-limiting Toxicity (DLT), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to AEs

Detailed description

Complete Response Rate (CRR)

Interventions

DRUGMK-3120

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Who Experience a Dose-limiting Toxicity (DLT), Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Treatment Due to AEs	—

Secondary

Measure	Time frame
Complete Response Rate (CRR)	—

Countries

Austria, Belgium, France, Greece, Italy, Netherlands, Norway, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026